Literature DB >> 1333901

Clinical aspects and epidemiology of hepatitis B and C viruses in hepatocellular carcinoma in Japan.

K Kiyosawa1, S Furuta.   

Abstract

The incidence of hepatocellular carcinoma (HCC) in Japan has increased over the past two decades. Of the 379 patients with HCC treated at Shinshu University Hospital over the past 20 years, 112 underwent treatment between 1971 and 1980 and 267 were treated between 1981 and 1990. The prevalence of hepatitis B virus-associated HCC and hepatitis C virus-associated HCC was 54% and 34%, respectively, during the first decade and 31% and 60%, respectively, during the second decade. Major factors contributing to the increased incidence of HCC include an increase in the incidence of type C chronic hepatitis and an increase in the incidence of cirrhosis of the liver, which in turn are the result of blood transfusions received about 30 years ago. Donated blood testing positive for hepatitis C virus antibody is currently rejected from the blood supply. However, the occurrence of post-transfusion hepatitis with the potential to develop into HCC has not been entirely eliminated. In addition, there is an as yet unelucidated route of horizontal transmission of hepatitis C virus.

Entities:  

Mesh:

Year:  1992        PMID: 1333901     DOI: 10.1007/bf00687126

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  Prevalence of anti-HCV antibody in blood donors in the Tokyo area.

Authors:  J Watanabe; K Minegishi; T Mitsumori; M Ishifuji; T Oguchi; M Ueda; E Tokunaga; E Tanaka; K Kiyosawa; S Furuta
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

2.  Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis.

Authors:  J H Gilliam; K R Geisinger; J E Richter
Journal:  Ann Intern Med       Date:  1984-12       Impact factor: 25.391

3.  The significance of blood transfusion in non-A, non-B chronic liver disease in Japan.

Authors:  K Kiyosawa; Y Akahane; A Nagata; Y Koike; S Furuta
Journal:  Vox Sang       Date:  1982-07       Impact factor: 2.144

4.  Change of intrahepatic expression of hepatitis-B core antigen during the clinical course of type-B chronic hepatitis.

Authors:  S T Franca; K Kiyosawa; Y Imai; T Sodeyama; T Hayata; Y Nakano; M Nakamura; S Furuta
Journal:  Scand J Gastroenterol       Date:  1989-05       Impact factor: 2.423

5.  Antibodies to peptides detect new hepatitis B antigen: serological correlation with hepatocellular carcinoma.

Authors:  A M Moriarty; H Alexander; R A Lerner; G B Thornton
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

6.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

7.  Intrafamilial transmission of hepatitis C virus in Japan.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; S Shimizu; S Furuta; Y Miyazaki; Y Akahane; H Suzuki
Journal:  J Med Virol       Date:  1991-02       Impact factor: 2.327

8.  Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice.

Authors:  F V Chisari; K Klopchin; T Moriyama; C Pasquinelli; H A Dunsford; S Sell; C A Pinkert; R L Brinster; R D Palmiter
Journal:  Cell       Date:  1989-12-22       Impact factor: 41.582

9.  Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis.

Authors:  K Kiyosawa; Y Akahane; A Nagata; S Furuta
Journal:  Am J Gastroenterol       Date:  1984-10       Impact factor: 10.864

10.  X protein of hepatitis B virus resembles a serine protease inhibitor.

Authors:  S Takada; K Koike
Journal:  Jpn J Cancer Res       Date:  1990-12
View more
  2 in total

1.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

2.  Viral hepatitis and hepatocellular carcinoma.

Authors:  Peter P Michielsen; Sven M Francque; Jurgen L van Dongen
Journal:  World J Surg Oncol       Date:  2005-05-20       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.